3 citations · 3 across the 1 of their papers we have counts for
2 papers
stat.AP2023★ 3 cited
Design Considerations for a Phase II platform trial in Major Depressive Disorder
Michaela Maria Freitag, Dario Zocholl, Elias Laurin Meyer +5
Major Depressive Disorder (MDD) is one of the most common causes of disability worldwide. Unfortunately, about one-third of patients do not benefit sufficiently from available trea…
stat.AP2021
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials
Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf +3
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questio…